



The Study of Clinical Profiles of Vivax Malaria in Comparison with Falciparum Malaria in Children at a Tertiary Care Centre in Eastern Bihar

KEYWORDS

Severe malaria; Plasmodium falciparum; P. vivax

* Dr. Ankur Priyadarshi

Assistant Professor, Department of Pediatrics, J.L.N. Medical College & Hospital, Bhagalpur.
* Corresponding Author

Deepak Kumar

Department of Pediatrics, J.L.N. Medical College & Hospital, Bhagalpur

Akhilesh Kumar

Department of Pediatrics, J.L.N. Medical College & Hospital, Bhagalpur

ABSTRACT

Background: Malaria remains an important cause of morbidity and mortality in children and adults in countries where it is endemic. Malaria due to *Plasmodium vivax* (*P. vivax*) is usually thought to be causing benign malaria with low incidence of complications as compared to *P. falciparum* but severe malaria due to *P. vivax* infection is increasingly observed now a days. Organ failure in vivax malaria is caused by mechanisms of inflammation as well as sequestration. In this study we have compared the clinical profiles complications in vivax malaria with those in falciparum malaria. **Objectives:** this study was done to compare the clinical profiles and complications of *P. vivax* with *P. falciparum* malaria mono infection in children. **Material and Methods:** This retrospective observational study included malaria patients who were admitted to paediatric indoor ward of J.L.N. Medical college hospital, Bhagalpur, a tertiary care teaching hospital, in eastern Bihar, during a period from March 2015 to March 2016. **Inclusion criteria** were patients of age group <12 years in whom either *P. falciparum* or *P. vivax* was positive on rapid malaria antigen test or peripheral blood smear. Patients showing mixed infections were excluded from study. **Results:** A total of 75 subjects (mean age 5.5 ± 3.3 years) were included in the study. It consisted of 43 cases of vivax malaria and 32 cases of *P. falciparum*. The *P. vivax* cases consisted of 32 (74.4%) males and 11 (25.5%) females while *P. falciparum* cases consisted of 14 (43.7%) males and 18 (56.3%) females. There was no statistical significant difference found between clinical profiles as well as complications such as anaemia, thrombocytopenia, liver and renal dysfunction, ARDS, and cerebral malaria between *P. vivax* and *P. falciparum*. **Conclusion:** The present study conclude that *P. vivax* mono infection tends to have as similar clinical course and complications as compared to malaria due to *P. falciparum* mono infection in children.

Introduction

Malaria is one of the major public health problems of the country. India reports around one million malaria cases annually and contributes 80% of Southeast Asia malaria burden¹. It is one of the serious problems in our country due to inability to control disease in endemic areas, migration of the populations, and serious complication caused by the disease itself. In India, *P. falciparum* and *P. vivax* are the most common species causing malaria, their proportion being around 50% each. *P. falciparum* malaria causes more severe disease, mortality and morbidity so intensive measures have been implemented mainly against it. *Vivax Malaria* has long been considered to have a benign course with multiple relapses.^{4,5} The typical complications seen in *falciparum malaria* are not usually found in vivax mono-infections. But there are few evidences in the past decade from studies in the countries of Asia that *P. vivax* is able to cause severe disease. *P. vivax* is now also getting recognized as a major cause of severe and fatal malaria despite its low parasite density, increased deformability of infected RBC & paucity of parasite sequestration. This may be due to its several important biological differences accounting for these observations, which are the development of the dormant stage in the liver (hypnozoites) causing relapse and greater transmission potential of *P. vivax* at low parasite densities. *P. vivax* is the most common geographically widespread species of *Plasmodium* causing malaria in human beings. This study was carried out to compare the clinical profiles and complications of *P. vivax* with *P. falciparum* malarial infection in children in our hospital which is a tertiary care centre and caters to patients from Eastern Bihar and some parts of Jharkhand.

Materials and Methods

It is a retrospective observational study. The study was

conducted at paediatric Department of JLN Medical college hospital, Bhagalpur, a tertiary care teaching hospital, in eastern Bihar. The study included malaria patients who were admitted to paediatric indoor ward of the hospital, during the period from March 2015 to march 2016. Inpatient records from March 2015 to march 2016 were retrieved and scrutinized by using a Performa on the basis of the patient's demographic profile, clinical findings, investigations, treatment, and complications during this 12- month period. The institutional ethical committee approved the study.

Inclusion Criteria.

All slide positive and rapid diagnostic tests (RDT) that confirmed cases of malaria (*P. vivax* and *P. falciparum*) admitted and treated in JLN Medical college hospital, Bhagalpur

Age group up to 12 years were included.

Exclusion Criteria.

Those febrile patients with clinical diagnosis of malaria but without any evidence on smear or antigen testing for *P. vivax* and *P. falciparum* malaria.

Mixed Malarial infection of *P. Falciparum* and *P. Vivax*

The diagnosis and confirmation of species of *P. falciparum* and *P. vivax* malaria were established by thick and thin film of peripheral blood smear examination under oil immersion with giemsa stain and RDT. The rapid malaria antigen kit used in the present study was based on detection of lactate dehydrogenase (LDH) and histidine-rich protein-2 (HRP-2). Anaemia in this study was defined when Hb of patient was ≤ 9 gm% while, raised ALT was defined when ALT

elevated >3x upper limit of normal. Severe complicated malaria was categorized as per World Health Organization guidelines.⁶ Severe complicated malaria in the form of cerebral malaria, severe anemia (Hb < 5mg/dL), thrombocytopenia (platelet count < 1 lac/cumm), pancytopenia, jaundice (S. Bilirubin >3mg/dL), acute renal failure (serum creatinine >3mg/dL), acute respiratory distress syndrome, and multiorgan dysfunction was included in this study. Routine laboratory investigations included a complete blood cell count, peripheral smear examination, blood indices, and platelet count and these were sent immediately after admission of all the patients. Urine examination, liver and renal function tests, coagulation profile, cerebrospinal fluid study, chest radiograph, and blood culture were done whenever it was indicated.

Statistical Analysis. Statistical analyses were performed by using SPSS version 16 software. The data of the two groups were compared using the Fisher or chi square test appropriate for each parameter in the study.

Table 1: Baseline Clinical profiles & Lab. parameters of patients.

Baseline characteristics	<i>P. vivax</i> (n = 43)	<i>P. falciparum</i> (n = 32)	All patients (n = 75)
Age (years, mean SD)	5.3 (3.2)	5.7 (3.4)	5.5 (3.3)
Gender (male/female)	32/11	14/18	46/29
Weight for age (z score < -2)	5 (11.6%)	4 (12.5%)	9 (11.3)
Duration of fever (days, mean SD)	5.1 (4.01)	5.4 (2.6)	5.2 (3.3)
Length of hospital stay (days, mean SD)	4.5 (2.4)	5.0 (3.1)	4.7 (2.8)
Hemoglobin (gm%, mean SD)	7.80 (2.26)	8.1 (2.6)	7.97 (2.4)
Blood sugar (mg%, mean SD)	81.3 (16.02)	88.3 (13.2)	85.1 (14.7)

Results

A total of 75 cases (mean age 5.5±3.3 yrs) were included in the study. It consisted of 43 patients of *P. vivax* and 32 patients of *P. falciparum*. Baseline characteristics of both groups were similar without having any significant statistical differences (Table 1). One patient of each of *P. vivax* and *P. falciparum* was expired. Fever was present in 100% of both *P. vivax* and *P. falciparum* cases. Anemia was present in 39.5% and 43.7% cases of *P. vivax* and *P. falciparum*, respectively, while thrombocytopenia was present in 36.1% and 36.7% cases. Raised ALT and jaundice were present in 10.6% and 6.3% of *P. vivax* cases while the same were present in 6.2% and 9.3% cases of *P. falciparum*. ARDS was present in 4.2% cases of *P. vivax* and 3.1% cases of *P. falciparum*. Cerebral malaria was present in 4.2% and 6.2% of *P. vivax* and *P. falciparum* malaria cases, respectively. Bivariate relationship between clinical features and complications of *P. vivax* and *P. falciparum* malaria showed no statistical significant difference (Table 2)

Table 2: Comparison of various parameters between *P. vivax* and *P. falciparum* malaria at initial presentation.

Parameters	<i>P. vivax</i> (n (%))	<i>P. falciparum</i> (n (%))	P value
Splenomegaly	27 (62.7)	18 (56.2)	0.31
Anemia	17 (39.5)	14 (43.7)	0.23

Parameters	<i>P. vivax</i> (n (%))	<i>P. falciparum</i> (n (%))	P value
Thrombocytopenia	15 (34.8)	12 (37.5)	0.23
Jaundice	3 (6.3)	3 (9.3)	0.64
Raised ALT	6 (13.9)	4 (12.5)	0.47
Renal failure	1 (2.1)	1 (3.1)	0.40
ARDS	2 (4.2)	1 (3.1)	0.42
Cerebral malaria	2 (4.2)	2 (6.2)	0.35

Discussion

According to WHO report 2010, out of all malaria cases in South East Asia region more than 50% cases are of vivax.¹ Vivax malaria was always described as a benign disease. However in the past few years many cases of severe vivax malaria were seen and some cases resulted in death. And the status of *P. vivax* as a major threat affecting the world's most populous region is gaining attention. The belief that vivax malaria is rarely threatening and relatively benign is increasingly being challenged. Hence this study was done to compare the clinical profiles and complications of both the types of malaria i.e. *P. vivax* and *P. falciparum* in children. In this retrospective observational study we report 75 patients with *P. vivax* and *P. falciparum* malaria. Clinical profile and complication of *P. vivax* were similar to those caused by *P. falciparum* malaria which included anaemia, splenomegaly, thrombocytopenia, raised alanine aminotransferase (ALT), jaundice, renal failure, ARDS, and cerebral malaria. These findings of similar complication of *P. vivax* malaria were also reported by other authors.⁴⁻⁵ Thrombocytopenia is a well-known complication of *P. falciparum* malaria but also encountered in *P. vivax* malaria. This may be due to multiple factors which include increase in platelet destruction by platelet associated IgG antibody and its consumption. We observed thrombocytopenia in 34.8% in *P. vivax* group and 37.5% in *P. falciparum* group malarial children. Other authors from India also reported significantly higher proportion of thrombocytopenia in *P. vivax*. Raised ALT and jaundice were present in 13.9% and 6.3% cases of *P. vivax* while the same were present in 12.5% and 9.3% cases of *P. falciparum*. Hepatic involvement has been well documented in *P. falciparum* malaria but also reported in *P. vivax* malaria. The possible explanation for hepatic involvement is direct injury to liver by parasite leading to malarial hepatitis. Renal failure was encountered in 2.1% and 3.1% of *P. vivax* and *P. falciparum* cases in the present study, respectively. Renal failure was observed commonly in *P. falciparum* but also has been reported in *P. vivax* malaria. Renal failure in malaria is caused by parasitized red blood cells leading to mechanical obstruction. Microcirculatory disorders, disseminated intravascular coagulation, fluid loss, and hypoxic or immune-mediated necrosis of renal tubules and glomeruli are the possible mechanisms that may be implicated in vivax infection. Acute respiratory distress syndrome (ARDS) has been encountered in 3-4% cases of *P. vivax* and *P. falciparum* malaria. It is known to occur in *P. falciparum* malaria due to sequestration but not reported in *P. vivax* malaria very often. In our present study one patient of *P. vivax* died due to ARDS. The recent studies have shown that sequestration, cytokines, and nitric oxide production are mainly responsible for this complication of *P. vivax* malaria. Cerebral malaria has been observed in 4.2% of *P. vivax* and 6.2% of *P. falciparum* cases in our study. Cerebral malaria is a very severe complication and leading to one of the most common causes of mortality of malaria. One of our infected patients of *P. falciparum* malaria died due to cerebral malaria. Though exact pathogenesis of cerebral malaria in

P. vivax remains unknown, few studies suggested that it might be due to sequestration and cytokine mediated cerebral injuries. We believe that *P. vivax* malaria infection is often underestimated though complications and mortality are almost similar in comparison to *P. falciparum* malaria. Further large scale studies are required to know the exact pathogenesis of complications of *P. vivax* malaria. There is an urgent need of public health measures to estimate the burden of *P. vivax* malaria so that adequate planning and control measures can be taken against this emerging problem.

Limitations:

The major limiting factor of our study was its retrospective nature and the small sample size.

Conclusion

The study shows vivax as an important cause of morbidity and mortality from malaria among children in Eastern Bihar and nearby places. The present study shows vivax as quite an important cause of severe malaria. In fact a comparison of severe malaria cases shows no significant difference in severity vivax and falciparum.

Therefore present study concludes that ***P. vivax* mono infection tends to have as severe course and complications as compared to malaria due to *P. falciparum* mono infection in children.**

Acknowledgments:-

Authors are thankful to Dr. (Prof.) R. K. Sinha, HOD, Pediatrics, J.L.N. Medical college Bhagalpur, for his kind permission, guidance and infrastructural support.

Funding: None.

Competing interests: None

References

1. Estimation of True Malaria burden. World Health Report, Geneva, World Health Organization. 2008.
2. Severe *falciparum* malaria. World Health Organization, Communicable Diseases Cluster. *Trans R Soc Trop Med Hyg.* 2000; 94:S1-90.
3. Limaye CS, Londhey VA, Nabar ST. The study of complications of vivax malaria in comparison with falciparum malaria in Mumbai. *Journal of the Association of Physicians of India.* October 2012; Vol 60: 15-18.
4. Nadkar MY, Huche AM, Singh Raminder, Pazare AR. Clinical profile of severe *Plasmodium vivax* malaria in a tertiary care centre in Mumbai from June 2010-Jan 2011. *Journal of the Associations of physicians of India.* October 2012; Vol 6: 11-13.
5. D. K. Kochar, A. Das, S. K. Kochar et al., "Severe *Plasmodium vivax* malaria: a report on serial cases from Bikaner in northwestern India," *The American Journal of Tropical Medicine and Hygiene*, vol. 80, no. 2, pp. 194-198, 2009.
6. WHO, *Guidelines for the Treatment of Malaria*, WHO, 2nd edition, 2010.
7. World Health Organization, *Good Practices for Selecting and Procuring Rapid Diagnostic Tests for Malaria*, World Health Organization, Geneva, Switzerland, 2011.
8. Kochar D, Saxena V, Singh N, Kochar S, Kumar V, Das A. *Plasmodium vivax* malaria. *Emerg Infect Dis.* 2005; 11:132-34.
9. B. Genton, V.D'Acromont, L. Rare et al., "*Plasmodium vivax* and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea," *PLoS Medicine*, vol. 5, no. 6, Article ID e127, 2008.
10. Jat KR, Guglani V, Khairwa Anju. Severe and complicated *Plasmodium vivax* malaria in children. *Trop Doct.* Oct 2012; 42: 185-87.
11. C. S. Scott, D. van Zyl, E. Ho, L. Ruivo, B. Mendelow, and T. L. Coetzer, "Thrombocytopenia in patients with malaria: automated analysis of optical platelet counts and platelet clumps with the Cell Dyn CD4000 analyser," *Clinical & Laboratory Haematology*, vol. 24, no. 5, pp. 295-302,

- 2002.
12. K. Saravu, M. Docherla, A. Vasudev, and B. A. Shastry, "Thrombocytopenia in vivax and falciparum malaria: an observational study of 131 patients in Karnataka, India," *Annals of Tropical Medicine & Parasitology*, vol. 105, no. 8, pp. 593-598, 2011.
13. G. S. Tanwar, P. C. Khatri, C. K. Chahar et al., "Thrombocytopenia in childhood malaria with special reference to *P. vivax* mono-infection: a study from Bikaner (Northwestern India)," *Platelets*, vol. 23, no. 3, pp. 211-216, 2012.
14. D. K. Kochar, P. Singh, P. Agarwal, S. K. Kochar, R. Pokharna, and P. K. Sareen, "Malarial hepatitis," *Journal of Association of Physicians of India*, vol. 51, pp. 1069-1072, 2003.
15. C. Anand, C. Ramji, A. S. Narula, and W. Singh, "Malarial hepatitis: a heterogeneous syndrome?" *National Medical Journal of India*, vol. 5, no. 2, pp. 59-62, 1992.
16. S. Srivastava, S. Ahmad, N. Shirazi, S. Kumar Verma, and P. Puri, "Retrospective analysis of vivax malaria patients presenting to tertiary referral centre of Uttarakhand," *Acta Tropica*, vol. 117, no. 2, pp. 82-85, 2011.
17. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of *Plasmodium vivax* malaria. *Malar J* 2012; 11: 135.
18. R. Premaratna, A. K. E. Gunatilake, N. R. de Silva, Y. Tilakaratne, M. M. D. Fonseka, and H. J. de Silva, "Severe hepatic dysfunction associated with falciparum malaria," *Southeast Asian Journal of Tropical Medicine and Public Health*, vol. 32, no. 1, pp. 70-72, 2001.
19. Patwari, S. Aneja, A. M. Berry, and S. Ghosh, "Hepatic dysfunction in childhood malaria," *Archives of Disease in Childhood*, vol. 54, no. 2, pp. 139-141, 1979.
20. R. Singh, S. Kumar, S. K. Rana, B. Thakur, and S. P. Singh, "A comparative study of clinical profiles of vivax and falciparum malaria in children at a tertiary care centre in Uttarakhand," *Journal of Clinical and Diagnostic Research*, vol. 7, no. 10, pp. 2234-2237, 2013.